Literature DB >> 8638803

Sevoflurane versus isoflurane for maintenance of anesthesia: are serum inorganic fluoride ion concentrations of concern?

M E Goldberg1, J Cantillo, G E Larijani, M Torjman, D Vekeman, H Schieren.   

Abstract

Sevoflurane administration can result in increased serum inorganic fluoride ion concentrations, which have been associated with inhibition of renal concentrating ability. We measured serum fluoride levels, renal function, and recovery variables as a function of time in ASA grade I-III patients administered general anesthesia with isoflurane or sevoflurane for at least 1 h. Fifty patients were exposed to sevoflurane (< or = 2.4% inspired concentration) or isoflurane (< or = 1.9% inspired concentration) for maintenance of anesthesia as part of a multicenter trial. Blood was collected for determination of serum fluoride ion concentration, electrolytes, blood urea nitrogen, and creatinine at various time points pre- and postoperatively. Mean serum fluoride levels were significantly increased in sevoflurane versus isoflurane groups at all time points; the mean peak serum levels were 28.2 +/- 14 mumol/L at 1 h for sevoflurane and 5.08 +/- 4.35 mumol/L at 12 h for isoflurane. Sevoflurane-mediated increases in serum fluoride levels peaked at 1 h and, in general, decreased rapidly after discontinuation of the anesthesia. Three of 24 patients exposed to sevoflurane had one or more fluoride levels > 50 mumol/L. One of these patients had a serum inorganic fluoride ion level > 50 mumol/L at 12 h after sevoflurane, and an additional patient had fluoride levels > 33 mumol/L for up to 24 h after sevoflurane discontinuation. Those two patients also demonstrated an increase in serum blood urea nitrogen and creatinine at 24 h after sevoflurane administration compared with baseline. The elimination half-life of serum fluoride ion was 21.6 h. The results of this study suggest the possibility of sevoflurane induced nephrotoxicity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8638803     DOI: 10.1097/00000539-199606000-00029

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  8 in total

Review 1.  Sevoflurane in paediatric anaesthesia: a review.

Authors:  K L Goa; S Noble; C M Spencer
Journal:  Paediatr Drugs       Date:  1999 Apr-Jun       Impact factor: 3.022

2.  Pharmacokinetics of fluoride in toddlers after application of 5% sodium fluoride dental varnish.

Authors:  Peter Milgrom; Donald M Taves; Amy S Kim; Gene E Watson; Jeremy A Horst
Journal:  Pediatrics       Date:  2014-08-18       Impact factor: 7.124

3.  UCSF Protocol for Caries Arrest Using Silver Diamine Fluoride: Rationale, Indications and Consent.

Authors:  Jeremy A Horst; Hellene Ellenikiotis; Peter L Milgrom
Journal:  J Calif Dent Assoc       Date:  2016-01

Review 4.  Renal toxicity with sevoflurane: a storm in a teacup?

Authors:  B A Gentz; T P Malan
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 5.  Clinical pharmacokinetics of sevoflurane.

Authors:  M Behne; H J Wilke; S Harder
Journal:  Clin Pharmacokinet       Date:  1999-01       Impact factor: 6.447

Review 6.  Fluoride Exposure Induces Inhibition of Sodium-and Potassium-Activated Adenosine Triphosphatase (Na+, K+-ATPase) Enzyme Activity: Molecular Mechanisms and Implications for Public Health.

Authors:  Declan Timothy Waugh
Journal:  Int J Environ Res Public Health       Date:  2019-04-21       Impact factor: 3.390

Review 7.  The impact of sevoflurane anesthesia on postoperative renal function: a systematic review and meta-analysis of randomized-controlled trials.

Authors:  Rakesh V Sondekoppam; Karim H Narsingani; Trent A Schimmel; Brie M McConnell; Karen Buro; Timur J-P Özelsel
Journal:  Can J Anaesth       Date:  2020-08-18       Impact factor: 6.713

8.  Kidney function in living donors undergoing nephrectomy by sevoflurane or desflurane anesthesia.

Authors:  Min-Soo Kim; Jeong-Rim Lee; Myoung-Soo Kim; Sung-Yeon Ham; Seung-Ho Choi
Journal:  Yonsei Med J       Date:  2013-09       Impact factor: 2.759

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.